208 related articles for article (PubMed ID: 21693729)
1. ASCO 2011: broadening the horizons of cancer research.
Crane K
J Natl Cancer Inst; 2011 Jul; 103(13):999-1001. PubMed ID: 21693729
[No Abstract] [Full Text] [Related]
2. Researchers optimistic about sea change in cancer treatment.
Stephenson J
JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
[No Abstract] [Full Text] [Related]
3. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
4. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
5. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
Brunelli M; Manfrin E; Martignoni G; Bersani S; Remo A; Reghellin D; Chilosi M; Bonetti F
Am J Clin Pathol; 2008 Jun; 129(6):907-11. PubMed ID: 18480007
[TBL] [Abstract][Full Text] [Related]
6. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
7. Development trends for monoclonal antibody cancer therapeutics.
Reichert JM; Valge-Archer VE
Nat Rev Drug Discov; 2007 May; 6(5):349-56. PubMed ID: 17431406
[TBL] [Abstract][Full Text] [Related]
8. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
9. ASCO 2012: a good year for HER2 therapy.
Sledge GW
Clin Breast Cancer; 2012 Aug; 12(4):231. PubMed ID: 22858362
[No Abstract] [Full Text] [Related]
10. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
Dear R; Wilcken N; Shannon J
Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
[TBL] [Abstract][Full Text] [Related]
11. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Schmidt C
J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
[No Abstract] [Full Text] [Related]
12. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
13. Optimizing the delivery of targeted research: an opportunity for comparative effectiveness research.
Pritchard KI
J Clin Oncol; 2010 Mar; 28(7):1089-91. PubMed ID: 20124174
[No Abstract] [Full Text] [Related]
14. [Tyrosine kinases. New target of anticancer therapy].
Majsterek I; Pytel D; Błasiak J
Postepy Biochem; 2005; 51(3):251-60. PubMed ID: 16381169
[TBL] [Abstract][Full Text] [Related]
15. ASCO in the 21st century: challenges and opportunities--ASCO presidential address 2005.
Johnson DH
J Clin Oncol; 2006 May; 24(13):1967-71. PubMed ID: 16648494
[No Abstract] [Full Text] [Related]
16. Trial offers early test case for personalized medicine.
Garber K
J Natl Cancer Inst; 2009 Feb; 101(3):136-8. PubMed ID: 19176464
[No Abstract] [Full Text] [Related]
17. Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?
Entz-Werle N; Velasco V; Neuville A; Geoerger B; Mathieu MC; Guerin E; Kehrli P; Gaub MP; Vassal G; Grill J
Pediatr Blood Cancer; 2008 Jan; 50(1):163-6. PubMed ID: 16724315
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells: a step toward the cure.
Boman BM; Wicha MS
J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
[No Abstract] [Full Text] [Related]
19. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD
J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863
[No Abstract] [Full Text] [Related]
20. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
Workman P
Expert Rev Anticancer Ther; 2002 Dec; 2(6):611-4. PubMed ID: 12503197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
